candesartan cilexetil has been researched along with Ureteral Obstruction in 1 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Ureteral Obstruction: Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moriyama, T | 1 |
| Kawada, N | 1 |
| Akagi, Y | 1 |
| Ando, A | 1 |
| Horio, M | 1 |
| Yamauchi, A | 1 |
| Nagata, K | 1 |
| Imai, E | 1 |
| Hori, M | 1 |
1 other study available for candesartan cilexetil and Ureteral Obstruction
| Article | Year |
|---|---|
TCV-116 inhibits interstitial fibrosis and HSP47 mRNA in rat obstructive nephropathy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1997 |